PolyPid Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PYPD research report →
Range $10 – $13
Price Chart
About the company
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs.
- CEO
- Dikla Czaczkes Akselbrad
- IPO
- 2020
- Employees
- 72
- HQ
- Petah Tikva, HM, IL
Get TickerSpark's AI analysis on PYPD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $129.29M
- P/E
- -4.85
- Fwd P/E
- 7.03
- PEG
- -0.05
- P/S
- 0.00
- P/B
- 39.73
- EV/EBITDA
- -4.18
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -410.50%
- ROIC
- 0.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-32,967,000
- Net Income
- $-34,169,000-17.7%
- EPS
- $-2.09+57.4%
- OCF Growth
- +100.0%
- FCF Growth
- +100.0%
- 52W High
- $7.25
- 52W Low
- $3.50
- 50D MA
- $5.46
- 200D MA
- $4.83
- Beta
- 1.43
- RSI (14)
- 55
- Avg Volume
- 143.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
PolyPid said D-PLEX100 is on track for a November 28 PDUFA decision, with launch prep underway and multiple growth catalysts lined up in 2027-28.· November 11, 2026
- D-PLEX100 is in priority review, with labeling discussions underway and all scheduled FDA interactions said to be on track for the November 28 PDUFA goal date.
- PolyPid and Azurity are preparing for a U.S. launch in early 2027, while the company says the partner already contributed $30 million and has broader milestone potential.
- The company submitted its EMA MAA on September 14; EMA validation has begun formal review, with a decision expected in the second half of 2027 and a potential EU launch in 2028.
- Management highlighted label expansion beyond colorectal surgery as a major growth lever, starting with broader abdominal surgery and then potentially soft tissue and bone indications.
- Quarterly losses improved year over year, and management reiterated cash should fund operations into 2028 with expected commercialization proceeds and future milestones included.
PolyPid reported third-quarter 2026 research and development expense of $6.5 million versus $5.3 million in the third quarter of 2025; general and administrative expense of $1.5 million versus $1.8 million; and marketing and business development expense of $400,000, in line with the prior year. Net loss was $5.8 million, or $0.24 per share, compared with a net loss of $7.5 million, or $0.37 per share, in the prior-year quarter. For the first nine months of 2026, net loss was $21.3 million, or $0.94 per share, versus $25.7 million, or $1.72 per share, a year earlier. Cash, cash equivalents, and short-term deposits were $15.5 million at September 30, 2026, and management said this did not include the $15 million milestone payment that was received in early October after being recorded as a receivable. On guidance, management reiterated that cash resources, plus expected proceeds from the Azurity commercialization agreement and future potential proceeds, should fund operations into 2028 and through several significant milestones. They also said the NTAP decision is expected in August 2027, the EMA decision in the second half of 2027, and PD01b’s pre-IND meeting and first-in-human study are expected in the second half of 2027.
The CEO framed the quarter as a defining period with the company just over two weeks from its first PDUFA goal date for D-PLEX100. She emphasized that the FDA review is active, labeling discussions are underway, and the company is preparing for a U.S. launch subject to approval. She also positioned the business around three growth levers: expanding D-PLEX100’s label, moving into new geographies starting with Europe, and advancing the KinetiX pipeline with PD01b. Her tone was constructive and milestone-focused, with repeated emphasis that D-PLEX100 is intended to be the company’s first product, not its only one.
The CFO detailed a narrower quarterly loss profile and lower G&A year over year, with R&D up to $6.5 million from $5.3 million mainly because of NDA-related work and commercial readiness spending. G&A fell to $1.5 million from $1.8 million due primarily to lower noncash option expense tied to vesting after positive SHIELD II topline results. He said cash, cash equivalents, and short-term deposits were $15.5 million as of September 30, 2026, excluding the $15 million milestone payment received in early October. He also reiterated management’s view that current cash, plus expected Azurity proceeds and other potential proceeds, should support operations into 2028.
Analysts focused on label expansion, launch timing, NTAP adoption, FDA inspection status, pricing, milestone triggers, and evidence hospitals will need to adopt D-PLEX100. Management said label-expansion discussions with FDA are expected to start this quarter, but it is too early to know the agency’s requirements. On commercialization, they said launch will ramp account by account over several months, and that NTAP could make formulary adoption easier, although the company believes hospitals would still consider the product even without it. On pricing, Azurity will disclose launch pricing, and on milestones, management said there are over $290 million in development, regulatory, and sales milestones in the agreement, with development and regulatory milestones described as relatively short-term. For hospital adoption, management said existing health-economic data should be sufficient for launch, though some sites may conduct small pilot use cases of 7 to 10 patients to assess workflow rather than efficacy.
The bullish case from this call is that PolyPid is close to a binary regulatory catalyst with FDA review progressing on schedule and labeling discussions already underway. Management also pointed to multiple follow-on opportunities: a U.S. launch partner in place, NTAP potentially supporting adoption, EMA review underway, and label expansion plans that could broaden D-PLEX100 well beyond colorectal surgery. The pipeline story adds another layer, with PD01b advancing toward an FDA pre-IND meeting and first-in-human study in 2027.
The main risks are that the FDA decision is still pending and management would not comment on inspection status or label specifics, leaving approval and labeling uncertainty in place. Commercial uptake could also take months because adoption is account-by-account and depends on P&T review, hospital workflows, and surgeon engagement, even if management is optimistic. Label expansion, European commercialization, and pipeline progress are all still early-stage plans, and several of the milestone and launch timing assumptions depend on regulatory outcomes that have not yet occurred.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 61.2%
- Shares Outstanding
- 20.31M
- Float Shares
- 12.42M
of shares held by institutions
34 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 1.25M | ▼ 258.00K |
| Dafna Capital Management LLC | 207.90K | 0 |
| Marshall Wace, Llp | 199.75K | ▲ 84.73K |
| Rosalind Advisors, Inc. | 177.01K | ▼ 212.44K |
| Two Sigma Investments, LP | 145.02K | ▲ 145.02K |
| Renaissance Technologies LLC | 131.80K | ▲ 15.18K |
| Adar1 Capital Management, LLC | 103.95K | 0 |
| Jane Street Group, LLC | 98.22K | ▲ 15.10K |
| Susquehanna International Group, Llp | 80.45K | ▲ 40.43K |
| Citadel Advisors LLC | 53.78K | ▲ 11.50K |
| Lumbard & Kellner, LLC | 38.20K | 0 |
| Hrt Financial LP | 24.96K | ▼ 12.34K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Warshavsky Ori | other | 46,000 |
| May 11, 26 | Missulawin Jonathan | other | 49,000 |
| May 11, 26 | Hazan Dalit Fellous | other | 75,000 |
| Jul 15, 26 | Barenholz Yechezkel | other | 9,132 |
| Jul 15, 26 | Stein Robert Benjamin | other | 9,132 |
| Jul 15, 26 | Dror-Darwish Nir | other | 9,132 |
| Jul 15, 26 | BenAmram Joseph | other | 9,132 |
| Jul 15, 26 | Krinsky Itzhak | other | 9,132 |
| Jul 15, 26 | Story Brooke | other | 9,132 |
| Jul 15, 26 | Akselbrad Dikla Czaczkes | other | 149,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PYPD coverage
Recent articles, reports, and earnings notes.
No research on PYPD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PYPD report →PolyPid: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 11
PolyPid Ltd. (PYPD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
What PolyPid (PYPD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 11
PolyPid Provides Corporate Update and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 11
PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision
seekingalpha.com · Nov 4
PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript
seekingalpha.com · Oct 29
PolyPid to Report Third Quarter 2026 Financial Results and Operational Highlights on November 11, 2026
globenewswire.com · Oct 29
PolyPid Targets 2027 D-PLEX100 Launch, Unveils Diabetic Foot Infection Program
marketbeat.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.